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Abstract
Background: The present study evaluated the therapeutic effectiveness of moxidectin 1.0% (w/v) and imidacloprid
10% (w/v) (Advocate® spot-on solution for cats, Bayer Animal Health) against natural infections with the eyeworm
Thelazia callipaeda in cats. This study was conducted as a GCP, negative-controlled, blinded and randomised field
study in privately owned cats living in an area in southern Italy where T. callipaeda is enzootic.
Methods: The study was carried out in 30 cats (19 females and 11 males, aged from 8 months to 5 years, weighing
1.2–5.2 kg) of different breeds, naturally infected by T. callipaeda. At study inclusion (Day 0), animals were physically
examined and the infection level was assessed by examination of both eyes for clinical score and live adult T. callipaeda
count. Each cat was weighed and randomly assigned to one of the treatment groups (G1: Advocate, G2: untreated
control). Clinical assessments and T. callipaeda adult counts were performed on Day 14. At the study completion visit on
Day 28, clinical assessments and counts of T. callipaeda adults and larvae were performed. All cats were daily observed by
their owners and general health conditions were recorded during the entire period of the study.
Results: The primary effectiveness variable was the percentage of animals in G1 group (Advocate) showing a complete
elimination (parasitological cure) of adult eye worms at Day 14 and Day 28 . The effectiveness of the treatment in the G1
group was 93.3 and 100% at Day 14 and Day 28 , respectively, when compared to group G2. Total worm count reduction
from both eyes for Advocate was 96.3% on Day 14 and 100% on Day 28. Clinical data were confirmed by the examination
of conjunctival pouch flushing. An overall reduction in the number of cats with lacrimation and conjunctivitis was observed
following treatment despite the fact that in a few cats treated with Advocate clinical signs persisted due to the chronic
nature of the disease.
Conclusions: Based on the results of the present trial, a single dose of Advocate was found to be safe and highly effective
in the treatment of natural T. callipaeda infection in cats.
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Background
Thelazia callipaeda is a spiruroid nematode residing in
the conjunctival pouches of dogs, cats, wild carnivores
and humans. Since its first description in dogs from
northern Italy [1], reports of thelaziosis have increased
showing a wide distribution throughout European coun-
tries and its capability to provoke ocular manifestations
such as conjunctivitis, keratitis, corneal opacity and ulcers
[2–4] due to the mechanical action of the adult parasite on
the conjunctival and corneal epithelium. Due to its original
distribution in East Asian countries, this worm used to be
regarded as the “oriental eye-worm”, but after more recent
descriptions in animals and humans throughout European
countries such as Italy [5], Spain [6, 7], Croatia [8], Greece
[9], Serbia [10], Bulgaria and Hungary [11], this term is no
longer appropriate. The increase of infections in both
animals and humans is related to the presence of the T.
callipaeda vector, Phortica variegata, a drosophilid of
the subfamily Steganinae which, in Europe, acts as
intermediate host of the eyeworm [12, 13].
Phortica variegata live in forested and meadow areas
where several competent wild hosts (e.g. red foxes, wolves,
beech martens and wild cats [14]) perpetuate the infection,
being reservoirs of the infection to dogs and cats [15].
Among available treatment procedures, physical removal
of nematodes from conjunctival pouches consisting in a
saline rinse (effective for adult and immature nematodes)
and mechanical adult nematode collection by fine forceps
or swabs has been described [16]. For canine thelaziosis,
many treatments have been proposed, including topic
instillation of organophosphates [17] or moxidectin [18];
however, these had major local side effects.
In 2016, Otranto et al. [19] published results on the
effectiveness of moxidectin 2.5% w/v and imidacloprid
10% w/v (Advocate® spot-on solution for dogs, Bayer
Animal Health) in thelaziosis showing a high effectiveness:
a single application of this drug was sufficient to safely elim-
inate 100% of nematodes in infected dogs within seven days
after a single administration. Moreover, the latter formula-
tion acts systemically after topical application and conse-
quently ocular irritation as local side effect while treating
eye worm infections will not occur. In cats, the administra-
tion of milbemycin oxime at 2 mg/kg was demonstrated to
have a high effectiveness in the treatment of T. callipaeda
infections [20], but no registered products are currently
available for the treatment of thelaziosis in this species.
The aim of this study was to evaluate the effectiveness
of moxidectin 1.0% w/v and imidacloprid 10% w/v (Ad-
vocate spot-on solution for cats, Bayer Animal Health)
against natural T. callipaeda infection in cats.
Results
At baseline all cats were infected by T. callipaeda. The
average number of adult T. callipaeda specimens observed
in G1 and G2 was 2.13 and 1.87, respectively. The number
of parasites and the number of cats with clinical manifes-
tations (lacrimation, conjunctivitis and ocular discharge;
Table 1) in each eye was homogenous among groups
(F(1,28) = 0.767, P = 0.389 and Fisher’s exact test, P = 0.500,
for the number of parasites and for lacrimation, conjunc-
tivitis and ocular discharge, respectively). Keratitis and
ulcers were absent in all the cats. The number and per-
centage of cats positive for T. callipaeda infection at
each study day are reported in Table 2. Effectiveness in
G1 (Advocate) was 93.3% on Day 14 and 100% on Day
28. The total number and mean of live T. callipaeda
adults retrieved and counted on both eyes is reported
in Table 2. The reduction in the number of worms
counted in both eyes was 96.3% on Day 14 and 100% on
Day 28 for the treated group. A natural mild decrease was
observed for the untreated group showing a worm reduction
of 3.6% on Day 14 and 7.1% on Day 28. The comparison of
worm reduction between groups showed a significant differ-
ence at all post-treatment visits when tested by ANOVA
(F(1,28) = 67.600, P < 0.0001). Among ocular signs associated
with T. callipaeda presence, only lacrimation, conjunctivitis
and discharge were recorded in the included cats; details of
observed symptoms are reported in Table 1. None of the
cats exhibited keratitis and ulcers except one cat in the un-
treated group that showed both symptoms at the study clos-
ure visit (Day 28). A significant difference between treated
and control groups were observed for lacrimation on Day
Table 1 Number (and percentage) of cats showing clinical
manifestations associated to T. callipaeda infection at different
time points of the study
Symptom D0 D14 D28
Lacrimation
G1 10 (66.6) 5 (33.3) 5 (33.3)a
G2 9 (60.0) 10 (66.6) 11 (73.3)a
Conjunctivitis
G1 3 (20.0) 1 (6.7) 2 (13.3)b
G2 4 (26.7) 3 (20.0) 8 (53.3)b
Discharge
G1 1 (6.7) 0 (0) 0 (0)
G2 0 (0) 0 (0) 2 (13.3)
Keratitis
G1 0 (0) 0 (0) 0 (0)
G2 0 (0) 0 (0) 1 (6.7)
Ulcers
G1 0 (0) 0 (0) 0 (0)
G2 0 (0) 0 (0) 1 (6.7)
Abbreviations: G1 treated at D0 with Advocate, G2 untreated control, D
study day
aP = 0.028
bP = 0.020
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28 (Fisher’s exact test, P = 0.028) and for conjunctivitis on
Day 28 (Fisher’s exact test, P = 0.020). No treatment related
adverse effects were recorded.
Discussion
A single spot on application of Advocate, containing
moxidectin 1.0% (w/v) and imidacloprid 10% (w/v), was
highly effective in the treatment of feline thelaziosis.
Only one cat out of 15 treated was found positive two
weeks after treatment and no worms were detected four
weeks after treatment administration. No side effects
were observed during the whole study period. As was
previously demonstrated for dog patients [21], this com-
mercial formulation showed to be safe and effective for
the treatment of T. callipaeda infection in feline patients.
In this study a low prevalence of ocular clinical signs was
observed, confirming that the disease has a high variability
in the clinical presentation and that the occurrence of sub-
clinical asymptomatic infections is common. Even if some
clinical signs showed a significant reduction (lacrimation
and conjunctivitis) in treated cats, the observation of the
persistency of clinical signs in a few treated animals, also
following parasitological cure is due to the nature of the
disease that frequently has a chronic course. Concerning
the “One Health” approach, as reported elsewhere [15],
cases of human thelaziosis are reported in areas where the
infection is highly prevalent in the animal population. Cats
are hosts that can often reach high densities in peridomes-
tic habitats; therefore, a safe and effective drug being
approved for the treatment of feline thelaziosis repre-
sents an important asset in T. callipaeda control.
Conclusions
The results of the present study demonstrate that Advocate
is safe and highly effective in the treatment of T. callipaeda
infection in cats after single administration of the recom-
mended dose rate.
Methods
The study was conducted as a Good Clinical Practice
(GCP), negative controlled, blinded and randomized field
study in privately owned cats living in a T. callipaeda
enzootic area of the Basilicata region (southern Italy),
following approval by the Italian Ministry of Health
(DGSAF- 0028002-06/12/2016-DGSAF-MDS-P). Study
animals were located in areas enzootic for thelaziosis
where the presence of the vector and of the diseases in
dogs and cats was already proven [20, 22]. A sample
size of 30 cats, 15 per group, was estimated to detect a
difference between proportions (i.e. % of non-infected
cats) in treated animals versus untreated, assuming a
prevalence of infected cats in the untreated group of
73.3% (Motta et al. [20]) and a confidence level of 95%
[software nQuery+nTerim 3.0 (StatSols, Statistical
Solutions© Ltd. 2014). Thirty cats (19 females and 11
males) aged from 8 months to 5 years, of different
breeds, in good health conditions and with at least one
live adult T. callipaeda nematode in one eye (Fig. 1)
were included in the study following the collection of
the owner informed consent form. Details are provided
in Table 3.
At inclusion (D0) animals were physically examined,
weighed and inspected at both eyes, including a thorough
examination underneath the third eyelid to retrieve and
count live adult of T. callipaeda. Clinical manifestations
suggestive of eye worm infection such as lacrimation,
conjunctivitis, ocular discharge, keratitis, and ulcers,
were recorded and classified as absent, mild, moderate
or severe.
Allocation to study groups (G1: Advocate, G2: untreated)
was done in accordance with a random treatment alloca-
tion plan. In order to avoid bias due to the contact between
treated and untreated cats, animals of the same household
were allocated to the same study group. Advocate was
administered on the basis of the body weight, following the
instructions reported on the label of the commercial
Table 2 Number (and percentage) of cats positive for adult
Thelazia callipaeda, count and mean of detected adult
nematode, worm reduction and efficacy of treatment (G1)
during the study
Group Response variable D0 D14 D28
G1 Positive cats, n (%) 15 (100) 1 (6.7) 0
Adult count (mean) 32 (2.13) 1 (0.07) 0
Reduction % 96.3 100
G2 Positive cats, n (%) 15 (100) 15 (100) 15 (100)
Adult count (mean) 28 (1.82) 27 (1.80) 26 (1.73)
Reduction % 3.6 7.1
Efficacy % 93.3 100
Abbreviations: G1, treated at D0 with Advocate; G2, untreated control; D,
study day
Fig. 1 Thelazia callipaeda nematodes on the conjunctiva of a cat
from the study
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packaging to provide a minimum spot-on dose of 1.0 mg/kg
moxidectin and 10 mg/kg imidacloprid.
On Day 14 and Day 28 (study closure) cats were
physically examined and the infection was evaluated by
inspection of both eyes, including conjunctival pouches
and third eyelids for live adult T. callipaeda count and
clinical scores.
At Day 28, the final visit, the conjunctival pouch of
both eyes of each animal was flushed twice with 2.5 ml
of 0.9% saline solution to collect samples for the evalu-
ation of the presence of T. callipaeda adults and larvae.
The instilled liquid was recollected by placing a Petri
dish right under the eye and transferred into a tube that
was centrifuged for 5 min at 700× g. The supernatant
was aspirated and the sediment (1 ml solution) assessed
by microscopic examination (40×) for the presence of
parasite stages. Nematodes were counted and morpho-
logically identified according to Skrjiabin et al. [23] and
Otranto et al. [24].
From Day 0 to Day 28 all cats were observed daily by
their owners to assess and record potential abnormalities
of the general health and, in case of their occurrence,
the veterinarian was responsible for examining the cat
and recording results of the clinical examination.
The primary variable for the effectiveness evaluation
was the number of cats showing a complete elimination of
adult eye worms on Day 14 and Day 28 by comparison of
G1 (treated cats) and G2 (untreated cats). As secondary
descriptive parameters, worm count, presence and/or
severity of ocular clinical signs were calculated and
compared between the two groups on Day 14 and Day
28. Effectiveness (%) in the treatment of T. callipaeda
infection was calculated for each time point using the
following formula:
Effectiveness %ð Þ ¼ Positive animals in the untreated group
Positive animals in the treated groupÞ
=Positive animals in the untreated group
100
Effectiveness was claimed if a significant difference
between groups G1 and G2 was demonstrated by
Fisher’s exact test calculated on contingency tables
for parasitological cure with 5% significance level of
probability of rejecting the null hypothesis.
Worm count and ocular clinical signs reductions in
the treated group were compared at time points (t) Day
14 and Day 28 with the untreated group as follows:
%reduction t½  ¼ Ct0  Ctð Þ=Ct0Þ  100;
where Ct0 was the baseline count before treatment and
Ct was the count at time t after treatment for each sec-
ondary variable under investigation. The significance of
the worm count reduction in treated cats was analyzed
by ANOVA with standard statistical assumption. Statis-
tical analysis was planned and conducted in compliance
with current guidelines [25]. Statistical calculations and
randomization were performed with: SPSS® statistical
package for Windows, v.23.0 and nQuery + nTerim 3.0
(StatSols).
Abbreviations
GCP: Good Clinical Practice; G1: Study group of cats treated with
imidacloprid 10% and moxidectin 1.0% spot-on; G2: Study group of
untreated cats; Day 0: Day of inclusion of selected cats; Day 14: 14th day of
the study; Day 28: 28th day of the study, closure
Acknowledgements
The authors thank Viviana Tarallo (Dipartimento di Medicina Veterinaria,
Università degli Studi di Bari) for her work with the administrative
procedures of the study; Egidio Mallia of the veterinary services of the Parco
Regionale di Gallipoli Cognato Piccole Dolomiti Lucane (Matera) for his
support during the field studies; and Roland Schaper (Bayer Animal Health
GmbH, Leverkusen, Germany) for his useful advice.
Funding
This study was funded by Bayer Animal Health.
Availability of data and materials
Data supporting the conclusions of this article are included within the article.
Raw data of this study are available at the Department of Veterinary
Medicine, University of Bari.
Authors’ contributions
DO, FSB, MGP and GP conceived and designed the study. RPL and DO
carried out the field activities. GC carried out the statistical analyses. RN
monitored the study. FSB, LF and DO drafted the first version of the
manuscript; the other authors critically reviewed the manuscript. All authors
read and approved the final manuscript.
Ethics approval
The study was approved by the Italian Ministry of Health (DGSAF- 0028002-
06/12/2016-DGSAF-MDS-P).
Consent for publication
Not applicable.
Competing interests
MGP and GP are employees of Bayer Animal Health GmbH, which funded
the study. DO, FSB, RPL, LF and GC declare that they have no competing
interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Table 3 Description of the characteristics of the cats included
in the study. Ranges for age and weight are reported in
parentheses
G1 (n = 15) G2 (n = 15) Total (n = 30)
Age (months) 20.7 (8–60) 23.5 (9–48) 22.1 (8–60)
Sex (no. of cats)a 12/3 7/8 19/11
Weight (kg) 2.7 (1.2–5.2) 2.8 (1.2–4.3) 2.8 (1.2–5.2)
Hair length (no. of cats)b 0/14/1 0/12/3 0/26/4
Abbreviations: G1 treated at D0 with Advocate, G2 untreated control
aFemale/Male
bLong/Medium/Short
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